Last reviewed · How we verify
NCT06848166
Study of the Effectiveness and Safety of Embolization of the Middle Meningeal Artery Using Non-adhesive Materials SQUID 12 and SQUID 18 in the Treatment of Patients With Chronic Resistant Migraine
EARLY_PHASE1 trial testing liquid embolic agent SQUID 12, liquid embolic agent SQUID 18 in Chronic Migraine Headache in 30 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Vedanta University Clinic |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 25 October 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 May 2027 |
| Sites | 1 location across Kyrgyzstan |
Drugs / interventions tested
- liquid embolic agent SQUID 12, liquid embolic agent SQUID 18
Conditions studied
- Chronic Migraine Headache — all drugs for Chronic Migraine Headache →
Sponsor
Vedanta University Clinic
Who can join
Adults 35 to 59, any sex, with Chronic Migraine Headache. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
number of migraine days
Time frame: From previous 4 weeks before enrollment to the 3 months (12 weeks) post-surgery
Change from baseline (during the screening period) in the number of migraine days over the previous 4 weeks, assessed at 3 months (12 weeks) post-surgery
Sponsor's own description
To evaluate the effectiveness and safety of middle meningeal artery (MMA) embolization using non-adhesive materials SQUID 12 and SQUID 18 as a treatment method for patients with chronic resistant migraine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06848166
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Migraine Headache
Currently open trials in the same condition.
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07347067 — Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine · NA · recruiting
- NCT07040813 — The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs · Phase 3 · recruiting
- NCT06652724 — Relieving Chronic Pain: Psychosomatic Mechanisms and Psychological Interventions in Fibromyalgia and Chronic Headache · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06848166 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vedanta University Clinic
- Last refreshed: 21 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06848166.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing